A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE)
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Rationale: This is the first multicenter randomized controlled trial to evaluate the effectiveness and safety of Zephyr Endobronchial Valve (EBV) in patients with little to no collateral ventilation out to 12 months. Objectives: To evaluate the effectiveness and safety of Zephyr EBV in heterogeneous emphysema with little to no collateral ventilation in the treated lobe. Methods: Subjects were enrolled with a 2:1 randomization (EBV/standard of care [SoC]) at 24 sites. Primary outcome at 12 months was the ΔEBV–SoC of subjects with a post-bronchodilator FEV1 improvement from baseline of greater than or equal to 15%. Secondary endpoints included absolute changes in post-bronchodilator FEV1, 6-minute-walk distance, and St. George’s Respiratory Questionnaire scores. Measurements and Main Results: A total of 190 subjects (128 EBV and 62 SoC) were randomized. At 12 months, 47.7% EBV and 16.8% SoC subjects had a ΔFEV1 greater than or equal to 15% (P < 0.001). ΔEBV–SoC at 12 months was statistically and clinically significant: for FEV1, 0.106 L (P < 0.001); 6-minute-walk distance, +39.31 m (P = 0.002); and St. George’s Respiratory Questionnaire, −7.05 points (P = 0.004). Significant ΔEBV–SoC were also observed in hyperinflation (residual volume, −522 ml; P < 0.001), modified Medical Research Council Dyspnea Scale (−0.8 points; P < 0.001), and the BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index (−1.2 points). Pneumothorax was the most common serious adverse event in the treatment period (procedure to 45 d), in 34/128 (26.6%) of EBV subjects. Four deaths occurred in the EBV group during this phase, and one each in the EBV and SoC groups between 46 days and 12 months. Conclusions: Zephyr EBV provides clinically meaningful benefits in lung function, exercise tolerance, dyspnea, and quality of life out to at least 12 months, with an acceptable safety profile in patients with little or no collateral ventilation in the target lobe. Clinical trial registered with www.clinicaltrials.gov (NCT 01796392).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lung volume reduction (LVR), performed by either surgical or bronchoscopic approach, is an option for a subset of COPD patients with advanced emphysema who meet strict selection criteria. These procedures have been associated with improved lung function, exercise capacity, and quality of life.(181–183)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [182]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interpretative strategies for lung function tests
Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R. O., Burgos, F., Casaburi, R., Coates, A., van der Grinten, C. P. M., Gustafsson, P., Hankinson, J., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00035205 · Cited by 5,945 · cited 1×
“Although the MCID cut off for change in FEV1 is highly variable, ranging from 10% to 15% (23), this threshold of 15% for the responder analysis was based on discussion with the Food and Drug Administration as the a priori threshold that they required for the pivotal U.”
BackgroundA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829 · cited 1×
“The Hochberg step-up procedure was used to control for multiple secondary endpoint analyses (21).”
MethodA randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071
Singh, S. J., Puhan, M. A., Andrianopoulos, V., Hernandes, N. A., Mitchell, K. E., Hill, C. J., Lee, A. L., Camillo, C. A., Troosters, T., Spruit, M. A., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00150414 · Cited by 935
Self-citationA Randomized Study of Endobronchial Valves for Advanced Emphysema
Sciurba, F. C., Ernst, A., Herth, F. J. F., Strange, C., Criner, G. J., Marquette, C. H., Kovitz, K. L., Chiacchierini, R. P., Goldin, J., & McLennan, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0900928 · Cited by 832 · cited 1×
“In the first randomized controlled trial of Zephyr EBV, VENT (Endobronchial Valve for Emphysema Palliation Trial), the coprimary endpoints of FEV1 and 6-minute-walk distance (6MWD) achieved statistical but not clinically meaningful improvements between groups (11).”
Self-citationMinimal Clinically Important Differences in COPD Lung Function
Donohue, J. F. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200053377 · Cited by 529 · cited 1×
“106 L signifies a meaningful important clinical change (24).”
Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation
Klooster, K., ten Hacken, N. H. T., Hartman, J. E., Kerstjens, H. A. M., van Rikxoort, E. M., & Slebos, D.-J. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507807 · Cited by 487 · cited 2×
“Subsequent experience with homogenous patients in other trials (15, 16) has established the applicability of this therapy to a broader population.”
Self-citationSciurba, F. C., Rogers, R. M., Keenan, R. J., Slivka, W. A., Gorcsan, J., Ferson, P. F., Holbert, J. M., Brown, M. L., & Landreneau, R. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604253341704 · Cited by 462 · cited 12×
“These improvements resulting from a reduction in hyperinflation and improved lung function are consistent with similar findings after LVRS and warrant further study (32).”
InfluentialSelf-citationThe minimal important difference of exercise tests in severe COPD
Puhan, M. A., Chandra, D., Mosenifar, Z., Ries, A., Make, B., Hansel, N. N., Wise, R. A., & Sciurba, F. (2011) · European Respiratory Journal · doi:10.1183/09031936.00063810 · Cited by 402
Self-citationEffect of Lung-Volume–Reduction Surgery in Patients with Severe Emphysema
Geddes, D., Davies, M., Koyama, H., Hansell, D., Pastorino, U., Pepper, J., Agent, P., Cullinan, P., MacNeill, S. J., & Goldstraw, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430402 · Cited by 399
Research works printed but not linked: 1
- Criner, 2018, Effectiveness of the Zephyr® endobronchial valves (EBV®) in patients with severe emphysema: clinical outcomes from LIBERATE, a multicenter RCT [abstract], A7752
Cited by
Chronic obstructive pulmonary disease
Christenson, S. A., Smith, B. M., Bafadhel, M., & Putcha, N. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00470-6 · Cited by 1,219
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease
Celli, B. R., & Wedzicha, J. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1900500 · Cited by 461
Chronic Obstructive Pulmonary Disease
Labaki, W. W., & Rosenberg, S. R. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202008040 · Cited by 376
Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review
Riley, C. M., & Sciurba, F. C. (2019) · JAMA · doi:10.1001/jama.2019.0131 · Cited by 258
Self-citation
Metadata
- Authors
- Criner, G. J., Sue, R., Wright, S., Dransfield, M., Rivas-Perez, H., Wiese, T., Sciurba, F. C., Shah, P. L., Wahidi, M. M., de Oliveira, H. G., Morrissey, B., Cardoso, P. F. G., Hays, S., Majid, A., Pastis, N., Kopas, L., Vollenweider, M., McFadden, P. M., Machuzak, M., Hsia, D. W., Sung, A., Jarad, N., Kornaszewska, M., Hazelrigg, S., Krishna, G., Armstrong, B., Shargill, N. S., & Slebos, D.-J.
- Affiliations
- Temple University (US)
- St. Joseph's Hospital and Medical Center (US)
- University of Alabama at Birmingham (US)
- University of Louisville (US)
- University of Pittsburgh (US)
- Royal Brompton Hospital (GB)
- Duke University (US)
- Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
- University of California, Davis (US)
- Universidade de São Paulo (BR)
- University of California, San Francisco (US)
- Beth Israel Deaconess Medical Center (US)
- Medical University of South Carolina (US)
- Houston Methodist (US)
- Orlando Health (US)
- University of Southern California (US)
- Cleveland Clinic (US)
- University of California, Los Angeles (US)
- Stanford Health Care (US)
- University Hospitals Bristol NHS Foundation Trust (GB)
- University Hospital of Wales (GB)
- SIU Medicine (US)
- Palo Alto Medical Foundation (US)
- QST Consultations Ltd., Allendale, Michigan
- Pulmonx (United States) (US)
- University Medical Center Groningen (NL)
- Corresponding author
- Criner, Gerard J.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-11-01
- Volume
- 198
- Issue
- 9
- Pages
- 1151-1164
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2785216066
- Cited by
- 428
- References
- 40
- Citations by year
- 2026: 41 · 2025: 49 · 2024: 80 · 2023: 57 · 2022: 40 · 2021: 44 · 2020: 50 · 2019: 50 · 2018: 16
- FWCI
- 30.14
- Type
- journal article
- Language
- en
- Open access
- green
- research.rug.nl
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by-nc)
- TUScholarShare (Temple University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
- Funders
- Pulmonx Corporation
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- endobronchial valves, heterogeneous emphysema, collateral ventilation, FEV1 improvement, 6-minute walk distance, St George's Respiratory Questionnaire, hyperinflation, dyspnea, BODE index, pneumothorax, lung volume reduction, chronic obstructive pulmonary disease, treatment efficacy and safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). https://app.cochat.ai/papers/10.1164/rccm.201803-0590oc
- The paper
- Criner, G. J., Sue, R., Wright, S., Dransfield, M., Rivas-Perez, H., Wiese, T., Sciurba, F. C., Shah, P. L., Wahidi, M. M., de Oliveira, H. G., Morrissey, B., Cardoso, P. F. G., Hays, S., Majid, A., Pastis, N., Kopas, L., Vollenweider, M., McFadden, P. M., Machuzak, M., . . . Slebos, D.-J. (2018). A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201803-0590oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.